Børresen A L, Berg K, Dahlén G, Gillnäs T, Ericson C
Artery. 1981;9(1):77-86.
The lipid lowering drug Gemfibrozil significantly increased the levels of HDL-apoproteins, apoA-I and apoA-II in a group of 20 Swedish hyperlipemic males who were given 1200 mg daily of the drug for 8 weeks and thereafter submitted to a 4 weeks placebo period. It strikingly increased serum reserve cholesterol in binding capacity (SRCBC). No change was observed in "free" apoA-I or inthe level of Lp(a) lipoprotein. The results suggest that the effect of Gemfibrozil on HDL, may be particularly striking on a subclass (or on subclasses) of HDL responsible for most of SRCBC. The findings suggest that Gemfibrozil may become a useful drug for hyperlipidemic people, if its safety in pharmacological doses can be established.
降血脂药物吉非贝齐显著提高了一组20名瑞典高脂血症男性的高密度脂蛋白载脂蛋白、载脂蛋白A-I和载脂蛋白A-II的水平。这些男性每天服用1200毫克该药物，持续8周，之后进入4周的安慰剂期。它显著提高了血清储备胆固醇结合能力（SRCBC）。未观察到“游离”载脂蛋白A-I或脂蛋白(a)水平的变化。结果表明，吉非贝齐对高密度脂蛋白的作用可能对负责大部分SRCBC的高密度脂蛋白亚类（或亚类）尤为显著。这些发现表明，如果能确定其药理剂量下的安全性，吉非贝齐可能成为高脂血症患者的一种有用药物。
